Kinney Drugs announces partnership with Cancer Service Program
GOUVERNEUR, N.Y. Kinney Drugs has put together an educational program to teach uninsured patients how to get free cancer screenings, the northern New York state regional chain announced Monday.
Under a partnership with the Cancer Service Program in Oneida, Herkimer and Madison counties, Kinney will have staff at eight stores on March 22 to discuss how patients can get free screenings for breast, cervical and colorectal cancer.
“The goal is to increase awareness of the free cancer screenings available to men and women who meet criteria set forth by the Cancer Service Program,” Kinney marketing manager Penny Perrone-Gray said. “We want the people in our communities to know how important it is to be screened for breast, cervical and colorectal cancer and to understand how early detection can save lives.”
Late-stage clinical trial of Avastin fails to meet expectations, Genentech says
SOUTH SAN FRANCISCO, Calif. A late-stage clinical trial of a Genentech drug for men with late-stage prostate cancer has failed, the biotech company announced Friday.
Genentech, part of Swiss drug maker Roche, announced that a phase 3 trial of Avastin (bevacizumab) combined with prednisone and the chemotherapy drug docetaxel did not extend the amount of time that patients survived, compared with chemotherapy and prednisone alone.
The drug already has approval from the Food and Drug Administration for treating tumors and cancers of the lungs, colon, rectum, breasts, kidneys and brain.
Abbott’s submits supplemental approval application for Lupron Depot to FDA
ABBOTT PARK, Ill. Abbott is hoping that the Food and Drug Administration will approve one of its drugs as a treatment for advanced prostate cancer.
The Chicago-based drug maker announced Thursday that the FDA accepted its supplemental approval application for Lupron Depot (leuprolide acetate) in the 45-mg strength. The drug, an injectable, works by suppressing production of testosterone for six months. It is currently available in 7.5-mg, 22.5-mg and 30-mg formulations that work for one, three and four months.
“For many patients with advanced prostate cancer, Lupron Depot is an important treatment option because it can help manage the symptoms of their disease,” Abbott VP global pharmaceutical development Eugene Sun said in a statement. “Abbott is seeking approval for a new six-month formulation to provide greater convenience and dosing flexibility to physicians and patients who could benefit form this medication.”